Zydus gets rights to gastro drug Actibile
India’s Zydus Healthcare, a wholly-owned subsidiary of Cadila Healthcare (BOM: 532321), has entered into a definitive agreement to acquire Actibile (ursodeoxycholic acid) from Albert David Limited (ADL).
The brand falls in the gastroenterology segment and is used for dissolving gall bladder stones. The deal will be financed through internal accruals. No further terms of the accord were revealed.
Speaking on the development, chairman and managing director of the group Pankaj Patel said: “The gastrointestinal segment has been one of our core focus segments and we have been working with the medical fraternity to serve patient needs better. I believe that this acquisition will strengthen our portfolio of brands and leverage our equity in this key segment.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze